rotate-mobile
Giovedì, 28 Marzo 2024
Salute

Polpharma Biologics Announces Global Commercialization Deal for Biosimilar Natalizumab, a Key Multiple Sclerosis Medicine



-


In Evidenza

Potrebbe interessarti

Polpharma Biologics Announces Global Commercialization Deal for Biosimilar Natalizumab, a Key Multiple Sclerosis Medicine

Today è in caricamento